Extrapleural pneumonectomy or supportive care: Treatment of malignant pleural mesothelioma?

Interactive Cardiovascular and Thoracic Surgery

Volumn 12, Issue 6, 2011, Pages 1040-1045

  Sharif, Sumera ^a   Zahid, Imran ^a   Routledge, Tom ^b   Scarci, Marco ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b GUY S HOSPITAL   (United Kingdom)

Author keywords

Extrapleural pneumonectomy; Malignant mesothelioma; Supportive care

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; GEMCITABINE; METHOTREXATE; MITOMYCIN; MITOXANTRONE; NAVELBINE;

ADULT RESPIRATORY DISTRESS SYNDROME; ANEMIA; ARTICLE; BLEEDING; BLOOD TOXICITY; CANCER PALLIATIVE THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CYTOREDUCTIVE SURGERY; DIAPHRAGM HERNIA; DRUG RESPONSE; HEART ATRIUM ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART SUPRAVENTRICULAR ARRHYTHMIA; HEMATOTHORAX; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; LEUKOPENIA; LUNG RESECTION; MORBIDITY; NEUTROPENIA; PARAPLEGIA; PLEURA EMPYEMA; PLEURA MESOTHELIOMA; PNEUMONIA; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RECURRENCE RISK; RECURRENT LARYNGEAL NERVE PALSY; RESPIRATORY FAILURE; SURGICAL MORTALITY; SYSTEMATIC REVIEW; THERAPY EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME;

AGED; BENCHMARKING; EVIDENCE-BASED MEDICINE; HUMANS; LENGTH OF STAY; MALE; MESOTHELIOMA; PALLIATIVE CARE; PATIENT SELECTION; PLEURAL NEOPLASMS; PNEUMONECTOMY; RECURRENCE; RISK ASSESSMENT; RISK FACTORS; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 79958743697     PISSN: 15699293     EISSN: 15699285     Source Type: Journal    
DOI: 10.1510/icvts.2010.256289     Document Type: Article

References (16)

1. Dunning J, Prendergast B, Mackway-Jones K. Towards evidence-based medicine in cardiothoracic surgery: best BETS. Interact CardioVasc Thorac Surg 2003;2:405-409.
2. Aziz T, Jilaihawi A, Prakash D. The management of malignant pleural mesothelioma; single centre experience in 10 years. Eur J Cardiothorac Surg 2002;22:298-305.
3. Ambrogi V, Mineo D, Gatti A, Pompeo E, Mineo TC. Symptomatic and quality of life changes after extrapleural pneumonectomy for malignant pleural mesothelioma. J Surg Oncol 2009;100:199-204.
4. Flores RM, Pass HI, Seshan VE, Dycoco J, Zakowski M, Carbone M, Bains MS, Rusch VW. Extrapleural pneumonectomy versus pleurectomyydecortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg 2008;135:620-6.
5. Nakas A, Trousse DS, Martin-Ucar AE, Waller DA. Open lung-sparing surgery for malignant pleural mesothelioma: the benefits of a radical approach within multimodality therapy. Eur J Cardiothorac Surg 2008;34:886-891.
6. Yan TD, Boyer M, Tin MM, Wong D, Kennedy C, McLean J, Bannon PG, McCaughan BC. Extrapleural pneumonectomy for malignant pleural mesothelioma: outcomes of treatment and prognostic factors. J Thorac Cardiovasc Surg 2009;138:619-624.
7. Van Sandick JW, Kappers I, Baas P, Haas RL, Klomp HM. Surgical treatment in the management of malignant pleural mesothelioma: a single institution's experience. Ann Surg Oncol 2008;15:1757-1764.
8. Schipper PH, Nichols FC, Thomse KM, Deschamps C, Cassivi SD, Allen MS, Pairolero PC. Malignant pleural mesothelioma: surgical management in 285 patients. Ann Thorac Surg 2008;85:257-264.
9. Aigner C, Hoda MA, Lang G, Taghavi S, Marta G, Klepetko W. Outcome after extrapleural pneumonectomy for malignant pleural mesothelioma. Eur J Cardiothorac Surg 2008;34:204-207.
10. Okada M, Mimura T, Ohbayashi C, Sakuma T, Soejima T, Tsubota N. Radical surgery for malignant pleural mesothelioma: results and prognosis. Interact CardioVasc Thorac Surg 2008;7:102-106.
11. Treasure T, Waller D, Tan C, Entwisle J, O'Brien M, O'Bryne K, Thomas G, Snee M, Spicer J, Landau D, Lang-Lazdunski L, Bliss J, Peckitt C, Rogers S, Marriage E, Coombes G, Webster-Smith M, Peto J. The mesothelioma and radical surgery randomised controlled trial. The Mars Feasibility Study. J Thorac Oncol 2009;4:1254-1258.
12. Pinto C, Marino A, De Pangher Manzini V, Benedetti G, Galetta D, Mazzanti P, Del Conte G, dell'Amore D, Piana E, Giaquinta S, Lopez M, Martoni A. Sequential chemotherapy with cisplatinygemcitabine (CG) followed by mitoxantroneymethotrexateymitomycin (MMM) in patients with malignant pleural mesothelioma. A multicenter Italian Phase II Study (SITMP1). Lung Cancer 2006;52:199-206.
13. Sørensen JB, Frank H, Palshof T. Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma. Br J Cancer 2008;99:44-50.
14. Martin-Ucar AE, Edwards JG, Rengajaran A, Muller S, Waller DA. Palliative surgical debulking in malignant mesothelioma. Predictors of survival and symptom control. Eur J Cardiothorac Surg 2001;20:1117-1121.
15. Shahin Y, Wellham J, Jappie R, Pointon K, Majewski A, Black E. How successful is lung-preserving radical surgery in the mesothelioma and radical surgery-trial environment? A case-controlled analysis. Eur J Cardiothorac Surg 2011;39:360-363.
16. Stahel RA, Weder W. Improving the outcome in malignant pleural mesothelioma: non-aggressive or aggressive approach? Curr Opin Oncol 2009;21:124-130.